Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE
This article was originally published in The Pink Sheet Daily
Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.
You may also be interested in...
NICE has rejected Novartis’ Afinitor for breast cancer, citing excessive cost and shooting down three out of four evidence submissions.
Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.